EU serialization requirements dictate what must appear on a medicine pack, who owns the serial data, what happens on the packaging line, and how pack data flows into the European system prior to supply. In practice, EU serialization requirements dictate that you must confirm whether a medicine is in scope, apply both the unique identifier data and an anti-tampering device to the outer pack, run controlled print and camera checks, and complete serial number reconciliation before batch closure. This article focuses on the pack level, enabling project managers, packaging engineers, and supply chain teams to translate these rules into a clear packaging plan. It does not provide legal advice, as scope must always be confirmed for the specific product and target market.
• EU serialization requirements impact artwork, carton layout, line setup, data handling, validation, and release planning.
• The 2D DataMatrix pharmacode and the anti-tampering device are two distinct safety features, meaning both must be planned correctly.
• The marketing authorisation holder remains accountable for product setup and serialization data, even when a packaging partner performs agreed-upon line tasks.
• Early planning helps prevent late-stage redesigns. Leaving considerations like code area, camera access, and tamper-evident placement until the last minute can cause significant problems on the line.
• A controlled project should define the scope, data ownership, exception handling, and quality agreement points well before running the first batch.
Why EU serialization requirements matter in a packaging project
EU serialization requirements matter because they fundamentally change both the pack and the process. They affect design, artwork, line equipment, batch data flow, and release timing. If a single element remains unclear, the entire batch can slow down. This article picks up where the basic definition stage ends. If your team needs a simpler overview first, our guide on what serialization means in pharmaceutical packaging provides valuable background information before you return to the project work detailed here.
Here, we focus on practical packaging execution. This includes explaining scope in plain language, detailing ownership, outlining line tasks, mapping data flow, and planning for the first batch. We do not determine whether a specific medicine is legally in scope, as that must be verified for each individual market. This distinction is crucial because medicine serialization requirements can differ by product category and country setup, even though the overall EU framework is shared.
The legal basis behind EU serialization requirements
The legal foundation stems from Directive 2011/62/EU and Commission Delegated Regulation (EU) 2016/161. The European verification system became applicable on 9 February 2019. For packaging teams, these legal details matter primarily because they create practical duties for the pack and the process. These responsibilities are embedded in the daily work of packaging, quality assurance, data handling, and release control.
The two safety features are separate
EU rules require two distinct safety features on many medicine packs. The first is the unique identifier, usually presented as a 2D DataMatrix code alongside related human-readable data. The second is an anti-tampering device, a physical feature that indicates whether the outer pack has been opened or altered. Because these features serve completely different functions, the code itself cannot act as the tamper-evident feature.
Which medicines are generally in scope
In simple terms, prescription medicines are generally in scope unless they appear in Annex I. Conversely, non-prescription medicines listed in Annex II are also in scope. Teams often wonder if small-volume or small-batch production alters these rules, but batch size has no bearing on scope. Even when discussing Annex I or Annex II medicines, teams should always verify the exact product and market before finalizing artwork and validation. This diligence is the safest way to apply EU serialization requirements during real-world project work.
What EU serialization requirements mean on the outer pack
At the pack level, EU serialization requirements mandate that the outer carton must carry the necessary identifier data alongside a physical anti-tampering device. This directly affects the print area, carton layout, readable text, camera views, and machine access on the packaging line. Small cartons and complex formats demand special attention; a drawing that looks perfectly workable on a screen can still fail during production if the code is difficult to print or read.
What the unique identifier normally contains
The unique identifier typically contains the product code, serial number, batch number, and expiry date. Additionally, some markets may require a national reimbursement or identification number. Teams should confirm the exact data set prior to final artwork approval, as late changes can severely impact available print space and line settings. This is a core component of pack-level serialization, and teams should treat it as an engineering challenge just as much as an artwork task.
What an anti-tampering device does
An anti-tampering device is a physical feature applied to the outer pack. Its role is to provide clear evidence if the pack has been opened or altered. The device must suit the carton format, the packaging process, transport handling, and the end user's experience. Strategic placement is essential; a poor position can lead to line jams, weak application, or damage during distribution.
Why these decisions cannot wait until late artwork
Late changes are inherently risky because the code area, print contrast, camera sightlines, and tamper placement all require stable handling on the line. A carton might easily pass an artwork review yet fail in practice due to poor access for print heads or cameras. Therefore, we treat serialization as a critical part of early engineering and validation planning. Our approach to pharma packaging design and development frequently starts with these practical decisions, ensuring that a compliant drawing translates into a stable production reality.
Who owns what under EU serialization requirements
Clear ownership is essential under EU serialization requirements, as legal accountability and operational execution are not the same thing. The marketing authorisation holder remains accountable for both product setup and serialization data within a controlled process. While a packaging partner may handle agreed-upon tasks during the batch run, accountability for regulated product data does not automatically transfer to the site packing the medicine.
What stays with the marketing authorisation holder
The marketing authorisation holder controls the product setup, confirms the scope, and remains accountable for all serialization data. This includes overseeing the controlled process for serial creation and managing the product master data used within the system. Furthermore, the holder confirms exactly how the medicine is configured for each market. This distinction is vital because project teams sometimes confuse operational support with legal ownership.
What the packing partner can do in the agreed workflow
Depending on the agreed model, a packaging partner may generate, print, verify, reject, and reconcile serial numbers throughout the packaging operation. These are strictly operational tasks performed inside a controlled workflow. Our expertise in secondary contract packaging with serialization falls directly into this practical space, ensuring that line work, exception handling, and batch records are clearly defined before production ever begins. If your team is evaluating an EU FMD serialization service provider, it is important to carefully separate packaging support from legal accountability and software ownership.
A simple responsibility map for project teams
• Customer or marketing authorisation holder: Confirms product scope, owns regulated product setup, and remains accountable for serialization data.
• Regulatory team: Confirms market requirements, assesses pack text impact, and clarifies country-specific points.
• Data owner: Controls serial creation, batch data exchange, and repository status rules.
• Packing partner: Executes agreed line tasks, such as printing, verifying, handling rejects, and reconciling serial numbers.
• Artwork team: Defines the code area, designs a readable layout, and allocates space for the tamper-evident feature.
• Production and quality: Validates the process, manages exceptions, and confirms that batch records and status outputs are entirely complete.
How EU serialization requirements work on the line and in the data flow
EU serialization requirements work best when the physical flow of the packs matches the digital flow of the data. The serial number is handled within a controlled data process, applied to the pack, checked on the line, and then routed appropriately into the broader European medicines verification system. While packaging teams do not necessarily need deep software knowledge, they must maintain a clear understanding of where the batch data goes and who is responsible for confirming each step.
Data flow from batch packing to national verification
At a basic level, serials are prepared under an agreed-upon controlled process, the batch is packed, and the relevant data is sent to the authorized onboarding partner. From there, the data moves to the European Hub before reaching national verification systems. This specific route matters greatly because a printed code alone is insufficient. The data must successfully navigate the approved digital path so the pack can be verified later in the supply chain.
Pack-level serialization tasks on the line
On the production line, the work is direct and highly repeatable. A variable code is printed on the pack, read by a camera, and checked against the expected data. Any unreadable or incorrect packs must be rejected and handled according to batch rules. Afterward, every serial status must be reconciled. Serial number reconciliation involves verifying that the final batch picture exactly matches what was printed, accepted, rejected, damaged, sampled, or scrapped. This reconciliation is a crucial element of FMD serialization, as incomplete status data can delay batch closure and introduce significant release risks.
Commissioning, exceptions, and decommissioning at dispense
Commissioning means making a valid serial number available in the repository system prior to sale or distribution. In simpler terms, the pack becomes active within the approved data environment. Exception handling is equally critical. Damaged, scrapped, or sample packs require controlled status handling so they do not remain active in the system incorrectly. Later in the supply chain, an authorized dispenser, such as a pharmacist, verifies the pack and performs decommissioning at dispense. In certain defined scenarios, wholesalers and other healthcare settings may also verify or decommission these packs.
How to plan for EU serialization requirements early and avoid late redesign
The best time to address EU serialization requirements is long before the first batch reaches the line. If teams wait too long, issues with the code area, camera access, and tamper-evident placement can force a packaging redesign or significantly delay validation. Serialization must therefore be integrated into the wider packaging journey from the very beginning, as early choices regarding format and handling will inevitably impact line performance later on.
Serialization is step four in the packaging journey
We view serialization as step four in a much broader process: design, manufacturability, component production, packing and serialization, and finally, placing the finished pack into the patient’s hands. This sequence matters because pack-level serialization heavily depends on the choices made during earlier stages. Both primary and secondary packaging play vital roles in this full journey, even though the legal safety features ultimately sit on the outer carton.
Why complex packs need early manufacturability work
Complex packs perfectly illustrate why physical design and operational execution must be planned simultaneously. For example, a format featuring unusual folds, multiple compartments, or narrow print zones can severely limit where a code is placed and how effectively a camera reads it. The same logic applies to a 4-in-1 pack that separates into four mini packs, as the underlying structure affects movement, machine access, and stability throughout the packaging operation. Conducting early manufacturability work helps mitigate these risks well before validation begins.
Questions the project manager should settle before the first batch
• Is the product currently in scope for each intended market?
• Who formally owns serial creation under the controlled process?
• Who is responsible for approving the artwork code area and its readability?
• Where exactly will the anti-tampering device be positioned on the outer pack?
• How will damaged, scrapped, and sample packs be managed on the line?
• Who confirms the data upload, commissioning, and final status reconciliation?
• What specific details must be written into the quality agreement and the regulatory plan?
FAQ for packaging teams
Is every prescription medicine in scope?
No. While prescription medicines are generally in scope, exceptions exist if they appear in Annex I. Conversely, non-prescription products listed in Annex II are also in scope. Project teams should verify the scope for the exact medicine and market before finalizing artwork or batch plans.
Is batch size relevant for serialization scope?
No. The size of the batch does not determine whether a product falls into scope. Instead, scope depends entirely on the specific medicine and the market rules governing it.
Is the DataMatrix the same as the anti-tampering device?
No. The 2D DataMatrix pharmacode simply carries the necessary identifier data. The anti-tampering device is a distinct, physical feature designed to show whether the pack has been opened or altered.
Can a packaging partner manage serial numbers on the line?
Yes. A packaging partner may generate, print, verify, reject, and reconcile serial numbers under an agreed-upon workflow. The exact model will depend heavily on the project setup and the formal quality agreement.
Who is accountable for serialization data?
The marketing authorisation holder remains fully accountable for both the serialization data and the overall product setup. While a packaging partner can execute agreed operational tasks, legal accountability stays firmly with the holder.
What is the difference between commissioning and decommissioning?
Commissioning involves making a valid serial number available in the repository prior to sale or distribution. Decommissioning, on the other hand, marks the pack as supplied, dispensed, or otherwise removed from active circulation according to defined regulatory rules.
Next steps for a controlled implementation
If you are preparing for a first batch, you must confirm product scope, serial data ownership, line tasks, exception handling, and release checks as early as possible. Once finalized, document these decisions directly in the project quality agreement and the regulatory plan. Taking these steps helps turn EU serialization requirements into a smoothly controlled packaging process rather than a stressful, late-stage batch problem.
If your team still needs a clear view of open questions regarding pack design, production, and shared responsibilities, conducting a structured review can be highly beneficial before artwork, validation, and batch planning progress too far. You can start our packaging quickscan to effectively map any gaps and decide on your next actions in a practical, streamlined way.
Request a free sample now!
